Latest news with #CidaraTherapeutics
Business Insider
27-05-2025
- Business
- Business Insider
Citizens JMP Sticks to Their Buy Rating for Cidara Therapeutics (CDTX)
In a report released today, Roy Buchanan from Citizens JMP maintained a Buy rating on Cidara Therapeutics (CDTX – Research Report), with a price target of $47.00. The company's shares closed last Friday at $24.28. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Buchanan covers the Healthcare sector, focusing on stocks such as Cidara Therapeutics, Inovio Pharmaceuticals, and Arbutus Biopharma. According to TipRanks, Buchanan has an average return of -26.6% and a 26.50% success rate on recommended stocks. Currently, the analyst consensus on Cidara Therapeutics is a Strong Buy with an average price target of $40.40, a 66.39% upside from current levels. In a report released on May 23, Needham also maintained a Buy rating on the stock with a $35.00 price target.
Yahoo
13-05-2025
- Business
- Yahoo
Cidara Therapeutics to Participate in Two Upcoming Investor Conferences
SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will participate in the below investor conferences. Event: RBC Global Healthcare ConferenceDate: Wednesday, May 21, 2025Time: 10:00 AM ET Event: Jefferies Global Healthcare ConferenceDate: Wednesday, June 4, 2025Time: 11:40 AM ET The live webcast for the presentations can be accessed in the Investors section on the Company's website at Replays of the presentations will be available for at least 30 days. Cidara will also participate in one-on-one investor meetings during these events. About Cidara TherapeuticsCidara Therapeutics is using its proprietary Cloudbreak® platform to develop novel drug-Fc conjugates (DFCs) comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment (Fc). Cidara's lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA), and the Company announced completion of Phase 2b enrollment in December 2024. Additional DFCs have been developed for oncology and in July 2024 Cidara received IND clearance for CBO421 which is intended to target CD73 in solid tumors. Cidara is headquartered in San Diego, California. For more information, please visit INVESTOR CONTACT:Brian RitchieLifeSci Advisors(212) 915-2578britchie@ MEDIA CONTACT:Michael FitzhughLifeSci Communicationsmfitzhugh@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
09-05-2025
- Business
- Yahoo
Cidara Therapeutics Inc (CDTX) Q1 2025 Earnings Call Highlights: Promising Advances in ...
Release Date: May 08, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Cidara Therapeutics Inc (NASDAQ:CDTX) is advancing its CD 388 program, which aims to revolutionize influenza prevention with a novel drug conjugate. The CD 388 drug has shown promising preclinical data, published in Nature Microbiology, highlighting its potential as a universal antiviral for influenza A and B. The phase 2B Navigate study for CD 388 is underway, with dosing completed for over 5,000 subjects, and top-line data expected by the end of June. Cidara Therapeutics Inc (NASDAQ:CDTX) is in discussions with the FDA to potentially evaluate statistical significance in their phase 2B study due to the severity of the flu season. The company plans to initiate a phase 3 study in high-risk populations, focusing on those underserved by current vaccines and antivirals, in the spring of 2026. Cidara Therapeutics Inc (NASDAQ:CDTX) is currently a non-revenue generating company, which may pose financial sustainability challenges. The Navigate study was not initially powered for statistical significance, which could impact the robustness of the results. There is uncertainty regarding the pricing and market size for CD 388, with discussions on potential pricing above initial estimates. The company is still finalizing the definition of high-risk patient populations for its phase 3 study, indicating ongoing strategic planning. The final data for the phase 2B study, including pharmacokinetic data, will not be available until September, delaying comprehensive analysis. Warning! GuruFocus has detected 8 Warning Signs with CDTX. Q: Have you had discussions with the FDA regarding the statistical analysis for the Phase 2B study, or are those discussions still ongoing? A: Yes, we have had those discussions and look forward to sharing the statistical analysis plan update at our May 22nd R&D Day event. (Jeff Stein, CEO) Q: Historically, you've mentioned a potential patient population of 20 million. Do you see a broader opportunity than that, and what about pricing dynamics? A: Our thinking has evolved, and we see a substantial opportunity in high-risk comorbid and immune-compromised populations. We also see potential for pricing above the previously mentioned range, reflecting the product's value. More details will be shared at the R&D Day. (Jeff Stein, CEO and Jim Bidel, Chief Business Officer) Q: How should we think about CD 388's positioning amidst discussions about vaccines and evolving views on them? A: CD 388 is initially targeted at high-risk populations underserved by vaccines. There's potential for complementarity with vaccines, as CD 388 targets a different mechanism. We aim to develop it in conjunction with existing vaccines. (Jeff Stein, CEO) Q: Can you provide details on the primary endpoint for the Navigate study and the data collection process? A: The primary endpoint is preventive efficacy, evaluated by centrally confirmed influenza infection, which includes nasopharyngeal PCR positivity, body temperature, and symptom criteria. It's a robust evaluation to confirm symptomatic and severe flu. (Nicole Dorapan, Chief Medical Officer) Q: Are you expecting a dose-dependent response on efficacy in the Phase 2B study, and how important is it to see this dose response? A: We expect to see a dose dependence, but more importantly, an exposure dependence. The relationship between exposure and efficacy will be crucial, and we hope to discuss this when we disclose top-line data. (Jeff Stein, CEO) For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Washington Post
08-05-2025
- Business
- Washington Post
Cidara Therapeutics: Q1 Earnings Snapshot
SAN DIEGO — SAN DIEGO — Cidara Therapeutics Inc. (CDTX) on Thursday reported a loss of $23.5 million in its first quarter. On a per-share basis, the San Diego-based company said it had a loss of $1.66. Cidara Therapeutics shares have decreased 29% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $19.15, a rise of 47% in the last 12 months.
Yahoo
30-04-2025
- Business
- Yahoo
Cidara Therapeutics to Participate in The Citizens Life Sciences Conference
SAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will participate in The Citizens Life Sciences Conference. Details are as follows: Event: The Citizens Life Sciences Conference Date: Wednesday, May 7, 2025Time: 11:00 AM ET Format: Presentation Webcast: A replay of the presentation will be available in the Investors section on the Company's website at The replay of the presentation will be available for at least 30 days. Cidara will also participate in one-on-one investor meetings during this event. About Cidara TherapeuticsCidara Therapeutics is using its proprietary Cloudbreak® platform to develop novel drug-Fc conjugates (DFCs) comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment (Fc). Cidara's lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA), and the Company announced completion of Phase 2b enrollment in December 2024. Additional DFCs have been developed for oncology and in July 2024 Cidara received IND clearance for CBO421 which is intended to target CD73 in solid tumors. Cidara is headquartered in San Diego, California. For more information, please visit INVESTOR CONTACT:Brian RitchieLifeSci Advisors(212) 915-2578britchie@ MEDIA CONTACT:Michael FitzhughLifeSci Communicationsmfitzhugh@
